Immunocore to present at upcoming investor conferences
28 févr. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
15 févr. 2023 03h00 HE
|
Cytovation
Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces...
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
02 févr. 2023 02h00 HE
|
Anaveon
BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers
30 janv. 2023 09h15 HE
|
Aesther Healthcare Acquisition Corp.
Results outline novel bispecific antibody approach that generates strong anti-tumor response in malignant melanoma, holding potential to control important pathways in multiple cancer types Ocean...
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
23 nov. 2022 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
11 nov. 2022 09h00 HE
|
Immunocore Holdings Limited
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is...
Melanoma Market Is Likely to Upsurge USD 13.11 Billion with Excellent CAGR Of 11.8% by 2029, Size, Share, Trend, Demand, Challenges and Competitors Outlook
17 oct. 2022 11h29 HE
|
Data Bridge Market Research
BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Data Bridge Market research has a newly released expansive study titled “Melanoma Market” which guarantees you will remain better informed than your...
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
12 oct. 2022 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
06 oct. 2022 16h05 HE
|
Lyell Immunopharma, Inc
Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...
Advanced Dermatology and Cosmetic Surgery Provides Breast Cancer Patients and Survivors with Free Skin Cancer Screenings for Breast Cancer Awareness Month
20 sept. 2022 09h00 HE
|
Advanced Dermatology and Cosmetic Surgery
MAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, Advanced Dermatology and Cosmetic Surgery announces it will offer complimentary skin cancer screenings...